These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16643518)

  • 1. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
    Martha B; Croisier D; Durand D; Hocquet D; Plesiat P; Piroth L; Portier H; Chavanet P
    Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in Pseudomonas aeruginosa isolates from Pseudomonas mastitis.
    Chuanchuen R; Wannaprasat W; Ajariyakhajorn K; Schweizer HP
    Microbiol Immunol; 2008 Aug; 52(8):392-8. PubMed ID: 18667038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.
    Islam S; Jalal S; Wretlind B
    Clin Microbiol Infect; 2004 Oct; 10(10):877-83. PubMed ID: 15373880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
    Croisier D; Martha B; Piroth L; Chavanet P
    Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of MexXY and OpmG in aminoglycoside efflux in Pseudomonas aeruginosa.
    Chuanchuen R; Wannaprasat W; Schweizer HP
    Southeast Asian J Trop Med Public Health; 2008 Jan; 39(1):115-22. PubMed ID: 18567450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
    Plasencia V; Borrell N; Maciá MD; Moya B; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2574-81. PubMed ID: 17470655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT; Sheng MY; Zhang Y; Li Y
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA.
    Matsuo Y; Eda S; Gotoh N; Yoshihara E; Nakae T
    FEMS Microbiol Lett; 2004 Sep; 238(1):23-8. PubMed ID: 15336398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
    Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycoside resistance in
    Thacharodi A; Lamont IL
    J Med Microbiol; 2022 Jun; 71(6):. PubMed ID: 35708991
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction.
    Jeannot K; Sobel ML; El Garch F; Poole K; Plésiat P
    J Bacteriol; 2005 Aug; 187(15):5341-6. PubMed ID: 16030228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
    Hocquet D; Nordmann P; El Garch F; Cabanne L; Plésiat P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa.
    Mao W; Warren MS; Lee A; Mistry A; Lomovskaya O
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2001-7. PubMed ID: 11408215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
    Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis.
    McCormick C; Caballero A; Tang A; Balzli C; Song J; O'Callaghan R
    Curr Med Res Opin; 2008 Jun; 24(6):1569-75. PubMed ID: 18423106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
    Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G
    J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa.
    van Gennip M; Moser C; Christensen LD; Bjarnsholt T; Calum H; Jensen PØ; Christophersen L; Hougen HP; Ciofu O; Molin S; Givskov M; Høiby N
    J Antimicrob Chemother; 2009 Dec; 64(6):1241-50. PubMed ID: 19815632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.